TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia

Brain

Volumn 139, Issue 11, 2016, Pages 2983-2993

  James, Bryan D ^a   Wilson, Robert S ^a   Boyle, Patricia A ^a   Trojanowski, John Q ^b   Bennett, David A ^a   Schneider, Julie A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; dementia; epidemiology; neuropathology; TDP 43

Indexed keywords

TAR DNA BINDING PROTEIN; DNA BINDING PROTEIN; TDP-43 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; AMYGDALA; ARTERIOLOSCLEROSIS; ARTICLE; BRAIN INFARCTION; CLINICAL EVALUATION; COHORT ANALYSIS; COMMUNITY CARE; CYTOPLASM; DEMENTIA; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPAL SCLEROSIS; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEWY BODY; MALE; NEOCORTEX; NEUROPATHOLOGY; PRIORITY JOURNAL; TDP 43 PROTEINOPATHY; AUTOPSY; BRAIN; INDEPENDENT LIVING; METABOLISM; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ARTERIOLOSCLEROSIS; AUTOPSY; BRAIN; BRAIN INFARCTION; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; HUMANS; INDEPENDENT LIVING; MALE; PSYCHIATRIC STATUS RATING SCALES; TDP-43 PROTEINOPATHIES;

EID: 84994528898     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww224     Document Type: Article

References (58)

1. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007; 61: 435-45.
2. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006; 351: 602-11.
3. Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, et al. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol 2009; 117: 125-36.
4. Arnold SJ, Dugger BN, Beach TG. TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol 2013; 126: 51-7.
5. Arvanitakis Z, Capuano AW, Leurgans SE, Buchman AS, Bennett DA, Schneider JA. The relationship of cerebral vessel pathology to brain microinfarcts. Brain Pathol 2016. doi: 10. 1111/bpa. 12365. [Epub ahead of print]
6. Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011; 42: 722-7.
7. Attems J, Jellinger KA. Hippocampal sclerosis in Alzheimer disease and other dementias. Neurology 2006; 66: 775.
8. Bennett DA, Schneider JA, Aggarwal NT, Arvanitakis Z, Shah RC, Kelly JF, et al. Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology 2006a; 27: 169-76.
9. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006b; 66: 1837-44.
10. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Curr Alzheimer Res 2011; 9: 628-45.
11. Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush memory and aging project. Curr Alzheimer Res 2012; 9: 646-63.
12. Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS. The Rush memory and aging project: study design and baseline characteristics of the study cohort. Neuroepidemiology 2005; 25: 163-75.
13. Bennett DA, Wilson RS, Arvanitakis Z, Boyle PA, de Toledo-Morrell L, Schneider JA. Selected findings from the religious orders study and rush memory and aging project. J Alzheimers Dis 2013; 33 (Suppl 1): S397-403.
14. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002; 59: 198-205.
15. Bigio EH, Mishra M, Hatanpaa KJ, White CL 3rd, Johnson N, Rademaker A, et al. TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathol 2010; 120: 43-54.
16. Boyle PA, Wilson RS, Yu L, Barr AM, Honer WG, Schneider JA, et al. Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol 2013; 74: 478-89.
17. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
18. Buchman AS, Leurgans SE, Nag S, Bennett DA, Schneider JA. Cerebrovascular disease pathology and parkinsonian signs in old age. Stroke 2011; 42: 3183-9.
19. Chang XL, Tan MS, Tan L, Yu JT. The Role of TDP-43 in Alzheimer's disease. Mol Neurobiol 2016; 53: 3349-59.
20. Cykowski MD, Takei H, Van Eldik LJ, Schmitt FA, Jicha GA, Powell SZ, et al. Hippocampal sclerosis but not normal aging or Alzheimer disease is associated with TDP-43 pathology in the basal forebrain of aged persons. J Neuropathol Exp Neurol 2016; 75: 397-407.
21. Davidson YS, Raby S, Foulds PG, Robinson A, Thompson JC, Sikkink S, et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: Association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 2011; 122: 703-13.
22. Geser F, Prvulovic D, O'Dwyer L, Hardiman O, Bede P, Bokde AL, et al. On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol 2011; 95: 649-62.
23. Geser F, Robinson JL, Malunda JA, Xie SX, Clark CM, Kwong LK, et al. Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol 2010; 67: 1238-50.
24. Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res 2007; 1184: 284-94.
25. Hu WT, Josephs KA, Knopman DS, Boeve BF, Dickson DW, Petersen RC, et al. Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol 2008; 116: 215-20.
26. Jellinger KA, Attems J. Challenges of multimorbidity of the aging brain: A critical update. J Neural Trans 2015; 122: 505-21.
27. Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR, et al. Staging TDP-43 pathology in Alzheimer's disease. Acta Neuropathol 2014a; 127: 441-50.
28. Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, et al. Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathol 2016; 131: 571-85.
29. Josephs KA, Nelson PT. Unlocking the mysteries of TDP-43. Neurology 2015; 84: 870-1.
30. Josephs KA, Whitwell JL, Knopman DS, Hu WT, Stroh DA, Baker M, et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 2008; 70 (19 Pt 2): 1850-7.
31. Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol 2014b; 127: 811-24.
32. Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: Their relation to AD common pathology. Neuropathology 2009; 29: 566-73.
33. Keage HA, Hunter S, Matthews FE, Ince PG, Hodges J, Hokkanen SR, et al. TDP-43 pathology in the population: prevalence and associations with dementia and age. J Alzheimers Dis 2014; 42: 641-50.
34. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology 2005; 65: 1863-72.
35. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984; 34: 939-44.
36. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86.
37. Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, Bennett DA, et al. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol 2015; 77: 942-52.
38. Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 2010; 20: 66-79.
39. Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 2011; 134 (Pt 5): 1506-18.
40. Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 2009; 117: 137-49.
41. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-3.
42. Rauramaa T, Pikkarainen M, Englund E, Ince PG, Jellinger K, Paetau A, et al. TAR-DNA binding protein-43 and alterations in the hippocampus. J Neural Transm 2011; 118: 683-9.
43. Robinson JL, Geser F, Corrada MM, Berlau DJ, Arnold SE, Lee VM, et al. Neocortical and hippocampal amyloid-beta and tau measures associate with dementia in the oldest-old. Brain 2011; 134 (Pt 12): 3708-15.
44. SAS Institute Inc. SAS 9. 3 Help and documentation. Cary, NC: SAS Institute Inc.; 2011.
45. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 2009a; 18: 691-701.
46. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-204.
47. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009b; 66: 200-8.
48. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004; 62: 1148-55.
49. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer s disease. Neurobiol Aging 1997; 18 (4 Suppl): S1-2.
50. Tremblay C, St-Amour I, Schneider J, Bennett DA, Calon F. Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 2011; 70: 788-98.
51. Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 2008; 67: 555-64.
52. Wilson AC, Dugger BN, Dickson DW, Wang DS. TDP-43 in aging and Alzheimer's disease- A review. Int J Clin Exp Pathol 2011; 4: 147-55.
53. Wilson RS, Barnes LL, Krueger KR, Hoganson G, Bienias JL, Bennett DA. Early and late life cognitive activity and cognitive systems in old age. J Int Neuropsychol Soc 2005; 11: 400-7.
54. Wilson RS, Beckett LA, Barnes LL, Schneider JA, Bach J, Evans DA, et al. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 2002; 17: 179-93.
55. Wilson RS, Yu L, Trojanowski JQ, Chen EY, Boyle PA, Bennett DA, et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol 2013; 70: 1418-24.
56. Youmans KL, Wolozin B. TDP-43: A new player on the AD field Exp Neurol 2012; 237: 90-5.
57. Yu L, De Jager PL, Yang J, Trojanowski JQ, Bennett DA, Schneider JA. The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology 2015; 84: 927-34.
58. Zarow C, Weiner MW, Ellis WG, Chui HC. Prevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample. Brain Behav 2012; 2: 435-42.